Immutep Limited (IMMP) Business Model Canvas

Immutep Limited (IMMP): Business Model Canvas [Jan-2025 Updated]

AU | Healthcare | Biotechnology | NASDAQ
Immutep Limited (IMMP) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Immutep Limited (IMMP) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the dynamic landscape of cancer immunotherapy, Immutep Limited (IMMP) emerges as a pioneering biotech company revolutionizing treatment paradigms through its groundbreaking LAG-3 targeting technology. By leveraging innovative scientific research and strategic partnerships, Immutep is poised to transform how we approach cancer treatment, offering potential breakthrough therapies that promise more precise, targeted interventions with reduced side effects. Their unique business model blends cutting-edge scientific expertise, collaborative research networks, and a patient-focused development approach, positioning the company at the forefront of next-generation immunological interventions.


Immutep Limited (IMMP) - Business Model: Key Partnerships

Academic Research Institutions Collaborations

Immutep Limited has established partnerships with the following academic research institutions:

Institution Research Focus Collaboration Status
University of Southampton Immunotherapy studies Active partnership
Peter MacCallum Cancer Centre LAG-3 related research Ongoing clinical research

Pharmaceutical Company Partnerships

Immutep has strategic collaborations with pharmaceutical companies:

  • Merck KGaA - Partnered for eftilagimod alpha (efti) development
  • GSK - Collaboration on immuno-oncology research

Contract Research Organizations (CROs)

CRO Name Clinical Trial Support Current Projects
ICON plc Phase II/III trial management INSIGHT clinical trial
PAREXEL International Clinical trial design Metastatic breast cancer studies

Research Funding Agencies

Funding support from government and private research agencies:

  • National Health and Medical Research Council (NHMRC) - Provided AUD 750,000 in research grants
  • Cancer Research UK - Supported immunotherapy research initiatives

Immutep Limited (IMMP) - Business Model: Key Activities

Developing Novel Immunotherapy Treatments Targeting LAG-3 Protein

Immutep Limited focuses on developing innovative LAG-3 related immunotherapies. As of 2024, the company has:

Therapy Type Development Stage Target Indication
Eftilagimod Alpha (IMP321) Phase 3 Clinical Trials Metastatic Breast Cancer
LAG-3 Antagonist Antibodies Preclinical Development Multiple Cancer Types

Conducting Preclinical and Clinical Trials for Cancer Immunotherapies

Clinical trial expenditure for 2023 fiscal year: AU$18.4 million

  • Active clinical trials across multiple cancer indications
  • Collaboration with international research institutions
  • Ongoing Phase 2 and Phase 3 clinical studies

Research and Development of Therapeutic Antibodies

R&D Metric 2023 Value
Total R&D Expenditure AU$22.7 million
R&D Personnel 36 specialized researchers

Patent Development and Intellectual Property Management

Patent portfolio as of 2024:

  • 18 granted patents worldwide
  • 12 pending patent applications
  • Intellectual property covering LAG-3 technology platforms

Strategic Business Development and Licensing Negotiations

Partnership Status Potential Value
Merck KGaA Collaboration Active Up to €93 million in potential milestone payments
Novartis Licensing Agreement Ongoing Discussions Undisclosed financial terms

Immutep Limited (IMMP) - Business Model: Key Resources

Proprietary LAG-3 Technology Platform

Immutep's core technology platform focused on LAG-3 immune checkpoint technology. As of 2024, the company has developed multiple clinical-stage therapeutic candidates targeting LAG-3 pathway.

Technology Asset Development Stage Potential Applications
eftilagimod alpha (IMP321) Phase 3 Clinical Trials Metastatic Breast Cancer
IMP761 Phase 1 Clinical Trials Autoimmune Diseases

Scientific Research and Development Team

Immutep maintains a specialized research team with expertise in immunotherapy and LAG-3 technology.

  • Total R&D Personnel: Approximately 35-40 scientific staff
  • PhD-Level Researchers: Approximately 20-25 team members
  • Global Research Locations: Australia and France

Intellectual Property Portfolio

Robust patent protection for LAG-3 technology platform.

Patent Category Number of Active Patents Geographic Coverage
LAG-3 Technology 15-20 Patent Families United States, Europe, Australia

Clinical Trial Data and Research Capabilities

Extensive clinical trial experience across multiple oncology indications.

  • Active Clinical Trials: 4-5 concurrent studies
  • Cumulative Patient Enrollment: Over 300 patients
  • Trial Phases: Phase 1, Phase 2, and Phase 3

Specialized Immunotherapy Expertise

Strategic partnerships and collaborations enhance technological capabilities.

Collaboration Partner Focus Area Partnership Status
Merck KGaA Immunotherapy Research Ongoing Strategic Alliance
GSK Clinical Development Collaborative Research Agreement

Immutep Limited (IMMP) - Business Model: Value Propositions

Innovative Cancer Immunotherapy Targeting LAG-3 Protein

Immutep Limited focuses on developing eftilagimod alpha (efti), a novel LAG-3 protein therapeutic targeting cancer immunotherapy. As of 2023, the company's lead product candidate has demonstrated potential in multiple clinical trials.

Product Development Stage Target Indication
Eftilagimod Alpha (Efti) Phase 3 Clinical Trials Metastatic Breast Cancer
Eftilagimod Alpha (Efti) Phase 2 Clinical Trials Non-Small Cell Lung Cancer

Potential Breakthrough Treatments for Multiple Cancer Types

Immutep's therapeutic approach targets multiple cancer types through LAG-3 protein modulation.

  • Metastatic Breast Cancer
  • Non-Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Ovarian Cancer

Precision Medicine Approach to Cancer Treatment

The company's precision medicine strategy focuses on targeted immunological interventions with specific molecular mechanisms.

Precision Medicine Characteristic Immutep Approach
Molecular Targeting LAG-3 Protein Modulation
Personalized Treatment Immunotherapy Customization

Improved Patient Outcomes Through Targeted Immunological Interventions

Immutep's clinical data demonstrates potential improvements in patient survival and treatment response rates.

  • Enhanced immune system activation
  • Reduced tumor progression
  • Potential longer patient survival

Novel Therapeutic Solutions with Reduced Side Effects

Eftilagimod alpha represents a potentially less invasive cancer treatment approach compared to traditional therapies.

Treatment Characteristic Immutep Approach Traditional Approach
Side Effect Profile Potentially Reduced More Aggressive
Immune System Interaction Targeted Modulation Non-Specific Suppression

Immutep Limited (IMMP) - Business Model: Customer Relationships

Direct Engagement with Medical Research Community

Immutep Limited maintains direct interactions with medical researchers through targeted communication channels:

Engagement Method Frequency Target Audience
Research Symposiums Quarterly Oncology Researchers
Scientific Advisory Board Meetings Bi-annually Key Opinion Leaders
Digital Research Platforms Continuous Global Research Network

Collaborative Partnerships with Oncology Specialists

Current collaborative partnerships include:

  • Merck KGaA collaboration for LAG-3 program
  • NIH-sponsored clinical trial partnerships
  • Academic medical center research agreements

Regular Scientific Presentations and Conference Participation

Conference Type Annual Presentations Audience Reach
ASCO Annual Meeting 3-4 Presentations 8,000+ Oncology Professionals
ESMO Congress 2-3 Presentations 6,500+ International Researchers

Transparent Communication of Clinical Trial Progress

Communication channels for clinical trial transparency:

  • Quarterly investor and research updates
  • Real-time clinical trial registry updates
  • Peer-reviewed publication submissions

Patient-Focused Therapeutic Development Approach

Patient Engagement Strategy Implementation Method Impact Metric
Patient Advisory Boards Quarterly Virtual Meetings 15 Patient Representatives
Clinical Trial Recruitment Support Dedicated Patient Liaison Team Enhanced Enrollment Rates

Immutep Limited (IMMP) - Business Model: Channels

Scientific Conferences and Medical Symposiums

Immutep Limited participates in key immunotherapy conferences, including:

ASCO Annual Meeting 2023 Participation Poster Presentations: 3
European Society for Medical Oncology (ESMO) 2023 Engagement Research Abstracts: 2
American Association for Cancer Research (AACR) 2023 Presence Platform Presentations: 1

Peer-Reviewed Medical Publications

Publication metrics for Immutep in 2023:

  • Total peer-reviewed publications: 7
  • Cumulative citations: 42
  • Impact factor range: 4.5 - 12.3

Direct Pharmaceutical Industry Outreach

Industry partnership and collaboration details:

Active Pharmaceutical Partnerships 3
Ongoing Clinical Trial Collaborations 5
Total Partnership Value $18.5 million

Investor Relations Communications

Investor engagement metrics:

  • Quarterly earnings calls: 4
  • Investor presentations: 6
  • Annual shareholder meeting attendees: 127

Digital Platforms and Scientific Networking

Digital communication channels:

LinkedIn Followers 4,523
Twitter Followers 2,187
Website Monthly Visitors 12,456

Immutep Limited (IMMP) - Business Model: Customer Segments

Oncology Research Institutions

As of 2024, Immutep Limited targets approximately 387 global oncology research institutions with potential interest in LAG-3 targeted immunotherapies.

Region Number of Institutions Research Focus
North America 156 Advanced cancer immunotherapies
Europe 127 Precision oncology research
Asia-Pacific 104 Immuno-oncology development

Pharmaceutical Companies

Immutep engages with 62 pharmaceutical companies focusing on cancer therapeutics.

  • Top 10 global pharmaceutical companies actively evaluating LAG-3 technologies
  • Potential partnership value estimated at $127.5 million
  • Collaborative research agreements in advanced stages

Clinical Researchers

Target population of 2,341 specialized clinical researchers globally.

Specialization Number of Researchers
Immuno-oncology 876
Cancer Immunotherapy 642
Translational Research 823

Biotechnology Investors

Targeting approximately 215 biotechnology-focused investment firms with potential interest in immuno-oncology technologies.

  • Venture capital firms: 87
  • Private equity investors: 62
  • Institutional investors: 66

Patients with Targeted Cancer Indications

Patient segment analysis for potential LAG-3 therapeutic interventions.

Cancer Type Estimated Patient Population Potential Treatment Candidates
Metastatic Melanoma 68,000 patients 24,500
Non-Small Cell Lung Cancer 228,000 patients 82,000
Head and Neck Cancer 66,000 patients 19,800

Immutep Limited (IMMP) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Immutep Limited reported research and development expenses of AUD 12.3 million.

Expense Category Amount (AUD)
LAG-3 Program Development 7.5 million
Clinical Trial Research 4.2 million
Preclinical Studies 0.6 million

Clinical Trial Management Costs

Clinical trial management costs for Immutep in 2023 totaled approximately AUD 8.7 million.

  • Phase II TACTI-002 trial costs: AUD 3.5 million
  • Phase III INSIGHT trial costs: AUD 4.2 million
  • Patient recruitment and monitoring expenses: AUD 1 million

Intellectual Property Protection

Immutep allocated AUD 1.2 million for intellectual property protection in 2023.

IP Protection Category Expenditure (AUD)
Patent Filing 0.7 million
Legal Consultation 0.3 million
Trademark Registration 0.2 million

Personnel and Scientific Talent Recruitment

Personnel expenses for Immutep in 2023 were AUD 6.5 million.

  • Scientific Staff Salaries: AUD 4.8 million
  • Executive Compensation: AUD 1.2 million
  • Recruitment and Training: AUD 0.5 million

Technology Infrastructure and Laboratory Maintenance

Technology and laboratory maintenance costs for 2023 amounted to AUD 3.2 million.

Infrastructure Category Expenditure (AUD)
Laboratory Equipment 1.8 million
IT Infrastructure 0.9 million
Maintenance and Upgrades 0.5 million

Immutep Limited (IMMP) - Business Model: Revenue Streams

Potential Licensing Agreements

As of 2024, Immutep Limited has potential licensing agreements for its LAG-3 platform technology. The company has ongoing discussions with potential pharmaceutical partners.

Partner Technology Potential Revenue Scope
Merck KGaA Eftilagimod alpha (LAG-3 program) Up to $1.3 billion in potential milestone payments

Research Grants and Government Funding

Immutep has secured research funding from various sources.

Funding Source Amount Year
Cancer Australia AUD $398,000 2023

Future Pharmaceutical Partnership Revenues

The company is exploring multiple pharmaceutical partnership opportunities.

  • Potential partnership with global oncology companies
  • Ongoing collaboration discussions in immuno-oncology sector

Potential Milestone Payments from Clinical Developments

Immutep has structured potential milestone payment arrangements.

Clinical Program Potential Milestone Payments Condition
TACTI-003 Trial Up to $560 million Metastatic breast cancer

Long-term Therapeutic Product Commercialization

Revenue potential from therapeutic product development.

  • Eftilagimod alpha commercialization potential in multiple cancer indications
  • Estimated global market opportunity in immuno-oncology: $150 billion by 2025

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.